Data from 6,366 rheumatoid arthritis patients who started anti-TNF therapy with infliximab (Remicade), adalimumab (Humira) or etanercept (Enbrel) between January 1999 and July 2006 were analyzed by the researchers. Then this group were compared with other groups of rheumatoid arthritis patients, including 61,160 not taking medications, 4,015 taking methotrexate (the gold standard of treatment) and 4,105 taking combinations of disease-modifying anti-rheumatic drugs (other than TNF blockers).
240 first cancers were diagnosed during follow-up among patients who had no cancer history when they began anti-TNF treatment, according to the study authors. Compared to rheumatoid arthritis patients who didn't take anti-TNF drugs or those with no history of cancer, the researchers found that the relative cancer risk of anti-TNF therapy was 1.00 and remained unchanged for those taking immunosuppressant drugs for up to six years.
Team leader, Dr. Johan Askling from the Karolinska University Hospital in Stockholm, confirmed in a news release, "Our research indicates the overall cancer risk is the same for rheumatoid arthritis patients on immunosuppressant therapies and those not taking medications for the disease." However, "given several uncertainties, continued vigilance remains prudent."
Source: Rheumatoid Arthritis Treatment Doesn't Promote CancerPerhatian:
Dibebaskan menyalin sebagian ataupun keseluruhan isi blog ini demi kepentingan pendidikan kesehatan bagi masyarakat umum dengan ketentuan mencantumkan alamat link blog ini sebagai sumbernya.Apabila Anda ingin berlangganan berita terbaru dari Gigi Sehat Badan Sehat, daftarkanlah alamat email Anda dengan meng-klik kata berlangganan:
Berlangganan.
Berita terbaru dari Gigi Sehat Badan Sehat akan langsung dikirimkan ke email Anda.
Kembali ke halaman utama